Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Pacira BioSciences Inc shares valued at $146,208 were sold by RIKER LAUREN on Jun 04 ’25. At $26.21 per share, RIKER LAUREN sold 5,578 shares. The insider’s holdings dropped to 59,564 shares worth approximately $1.46 million following the completion of this transaction.
Also, WILLIAMS KRISTEN sold 14,376 shares, netting a total of over 377,226 in proceeds. Following the sale of shares at $26.24 each, the insider now holds 161,574 shares.
Before that, RIKER LAUREN had added 5,579 shares to its account. In a trade valued at $146,209, the Officer bought Pacira BioSciences Inc shares for $26.21 each.
As published in a research note from Truist on January 30, 2025, Pacira BioSciences Inc [PCRX] has been rated up from a Sell to a Hold and the price target has been revised to $25 from $8. Analysts at Truist downgraded the stock from ‘”a Buy”‘ to ‘”a Sell”‘ outlook in a report released in mid August. As of August 12, 2024, RBC Capital Mkts has decreased its “an Outperform” rating to a “Sector perform” for PCRX. Earlier on August 12, 2024, Raymond James downgraded its rating. Their new recommendation was “a Mkt perform” for PCRX stock which previously was a “an Outperform”.
Analyzing PCRX Stock Performance
On last trading session,, Pacira BioSciences Inc [NASDAQ: PCRX] rose 0.45% to $24.45. The stock’s lowest price that day was $23.5, but it reached a high of $24.59 in the same session. During the last five days, there has been a drop of approximately -8.56%. Over the course of the year, Pacira BioSciences Inc shares have jumped approximately 29.78%.
Support And Resistance Levels for Pacira BioSciences Inc (PCRX)
RSI (Relative Strength Index) is 40.17 on the 14-day chart, showing neutral technical sentiment.
Is Pacira BioSciences Inc subject to short interest?
Stocks of Pacira BioSciences Inc saw a sharp steep in short interest on 2025-05-30 dropping by -0.31 million shares to 5.83 million. Data from Yahoo Finance shows that the short interest on 2025-04-30 was 6.15 million shares. A decline of -5.38% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 6.67 of the overall float, the days-to-cover ratio (short ratio) decline to 6.67.
Which companies own the most shares of Pacira BioSciences Inc (PCRX)?
In terms of Pacira BioSciences Inc share price expectations, FactSet research, analysts set an average price target of 25 in the next 12 months, up nearly 2.71% from the previous closing price of $24.34. Analysts anticipate Pacira BioSciences Inc stock to reach 48 by 2025, with the lowest price target being 24. In spite of this, 6 analysts ranked Pacira BioSciences Inc stock as Buy at the end of 2025. On August 12, 2024, Piper Sandler assigned a price target of “a Neutral” to the stock and downgraded coverage with a $11.
